Privately-held Israeli firm Neuronix Ltd.’s de novo request for NeuroAD Therapy System is all set to be discussed by an FDA panel on March 21, 2019.The NeuroAD Therapy System is intended to provide concurrent neurostimulation and cognitive training for the treatment of mild to moderate Alzheimer's dementia.NeuroAD, which is based on Neuronix’s patented Non Invasive Cortical Enhancer (NICE) technology, is a novel, non-invasive medical device that combines two modalities concurrently namely, Focused Transcranial Magnetic Stimulation and Long-Term Potentiation.NeuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s disease in Europe.